Marker Therapeutics logo

Marker TherapeuticsNASDAQ: MRKR

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 July 2002

Next earnings report:

25 March 2025

Last dividends:

N/A

Next dividends:

N/A
$29.00 M
-73%vs. 3y high
28%vs. sector
-vs. 3y high
-vs. sector
-29%vs. 3y high
75%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Thu, 21 Nov 2024 00:11:59 GMT
$3.25+$0.06(+1.88%)

Dividend

No data over the past 3 years
$1.00 M$1.00 M

Analysts recommendations

Institutional Ownership

MRKR Latest News

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
globenewswire.com14 November 2024 Sentiment: POSITIVE

Marker Therapeutics to receive two grants from NIH Small Business Innovation Research (SBIR) program to support clinical investigation of MT-601 in patients with lymphoma and metastatic pancreatic cancer Marker Therapeutics to receive two grants from NIH Small Business Innovation Research (SBIR) program to support clinical investigation of MT-601 in patients with lymphoma and metastatic pancreatic cancer

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
globenewswire.com14 August 2024 Sentiment: POSITIVE

Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
GlobeNewsWire22 March 2024 Sentiment: POSITIVE

HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. This conference will be held virtually on March 26, 2024.

Why Is Marker Therapeutics (MRKR) Stock Up 27% Today?
InvestorPlace31 May 2023 Sentiment: POSITIVE

Marker Therapeutics (NASDAQ: MRKR ) stock is rising higher on Wednesday as investors react to positive pre-clinical news from the clinical-stage immuno-oncology company. Today's results come from a test of MT-601 in lymphoma cells.

What type of business is Marker Therapeutics?

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

What sector is Marker Therapeutics in?

Marker Therapeutics is in the Healthcare sector

What industry is Marker Therapeutics in?

Marker Therapeutics is in the Biotechnology industry

What country is Marker Therapeutics from?

Marker Therapeutics is headquartered in United States

When did Marker Therapeutics go public?

Marker Therapeutics initial public offering (IPO) was on 16 July 2002

What is Marker Therapeutics website?

https://markertherapeutics.com

Is Marker Therapeutics in the S&P 500?

No, Marker Therapeutics is not included in the S&P 500 index

Is Marker Therapeutics in the NASDAQ 100?

No, Marker Therapeutics is not included in the NASDAQ 100 index

Is Marker Therapeutics in the Dow Jones?

No, Marker Therapeutics is not included in the Dow Jones index

When was Marker Therapeutics the previous earnings report?

No data

When does Marker Therapeutics earnings report?

The next expected earnings date for Marker Therapeutics is 25 March 2025